BioDiem at Portugal flu conference

BioDiem [ASX: BDM] has presented data from the company's influenza vaccine research at the Third European Influenza Conference in Portugal.

The speakers included BioDiem's head of virology and non-executive director, Professor Larisa Rudenko.

Rudenko presented data from BioDiem's studies evaluating the body's immune response to a live attenuated influenza vaccine (LAIV).

The conference heard that the vaccine significantly stimulated the main factors of immunity, including anti-haemagglutination, local antibodies and cell immunity.

The LAIV research was completed at the Institute of Experimental Medicine in St Petersburg, Russia.

Recent years have seen the emergence of highly pathogenic influenza viruses such as avian flu. The LAIV research is an attempt to develop a vaccine that can more effectively fight these influenza strains.